Ignite Creation Date:
2025-12-26 @ 11:08 AM
Ignite Modification Date:
2025-12-29 @ 8:10 AM
Study NCT ID:
NCT06538012
Status:
RECRUITING
Last Update Posted:
2024-10-15
First Post:
2024-07-31
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
Sponsor:
Essen Biotech
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-08-20
Start Date Type:
ACTUAL
Primary Completion Date:
2026-09-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12-28
Completion Date Type:
ESTIMATED
First Submit Date:
2024-07-31
First Submit QC Date:
None
Study First Post Date:
2024-08-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-11
Last Update Post Date:
2024-10-15
Last Update Post Date Type:
ACTUAL